RBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $106.00 (from $107.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE